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Introduction: Psoriatic arthritis (PsA) is a distinctive inflammatory arthritis which may typically develop in a
subgroup of individuals suffering from psoriasis. We recently described progranulin autoantibodies (PGRN-Abs) in
the sera of patients with different autoimmune diseases including seronegative polyarthritis. In the present study
we investigated the occurrence of PGRN-Abs in PsA.
Methods: PGRN-Abs were determined in 260 patients with PsA, 100 patients with psoriasis without arthritic
manifestations (PsC) and 97 healthy controls using a recently described ELISA. PGRN plasma levels were determined
from subgroups by a commercially available ELISA-kit. Possible functional effects of PGRN-antibodies were analysed
in vitro by tumour necrosis factor (TNF)-α mediated cytotoxicity assays using WEHI-S and HT1080 cells.
Results: PGRN-Abs were detected with relevant titres in 50/260 (19.23%) patients with PsA, but in 0/100 patients
with psoriasis without arthritic manifestations (P = 0.0001). All PGRN-Abs belonged to immunoglobulin G (IgG).
PGRN-Abs were significantly more frequent in PsA patients with enthesitis or dactylitis. PGRN-Abs were also more
frequent in PsA patients receiving treatment with TNF-α-blockers than in patients treated without TNF-α-blockers
(20.8% versus 17.4%; P = 0.016). PGRN plasma levels were significantly lower in PGRN-Ab-positive patients with PsA
than in healthy controls and patients with psoriasis without arthritic manifestations (P < 0.001), indicating a
neutralizing effect of PGRN-Abs. Moreover cytotoxicity assays comparing PGRN-antibody positive with negative sera
from matched patients with PsA, clearly showed a proinflammatory effect of PGRN antibodies.
Conclusion: Neutralizing PGRN-Abs occur with relevant titres in a subgroup of patients with PsA, but not in
patients without arthritic manifestations (PsC). PGRN-Ab-positive patients had more frequent enthesitis or dactylitis.
TNF-α-induced cytotoxicity assays demonstrated that the protective effects of progranulin were inhibited by serum
containing PGRN-Abs. This suggests that PGRN-Ab might not only be useful as a diagnostic and prognostic marker,
but may provide a proinflammatory environment in a subgroup of patients with PsA.Introduction
Psoriatic arthritis (PsA) is a distinctive inflammatory
form of arthritis that may develop in 20% to 25% of indi-
viduals with psoriasis [1]. In addition to manifestations
of psoriasis in the skin, patients with PsA may present
with mild to very severe development of oligoarthritis* Correspondence: Lorenz.Thurner@uks.eu
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manifestations similar to spondyloarthritis. PsA has been
considered a seronegative inflammatory arthritis accord-
ing to the diagnostic criteria first published by Moll et al.
in 1973 [2] and then redefined by the Classification
Criteria for Psoriatic Arthritis (CASPAR) [3]. All defi-
nitions of PsA have in common the seronegative status of
the disease because autoantibodies (Abs) such as rheuma-
toid factor (RF), anticyclic citrullinated autoantibodies and
antinuclear autoantibodies are usually absent in PsA.
Hence, in contrast to rheumatoid arthritis, autoreactive Bl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[4]. Regarding the occurrence of autoantibodies in PsA, in-
creased frequencies of thyreoglobulin Abs (14.29%) and
thyroid peroxidase Abs (23%) were reported in PsA, which
was explained by a relatively high comorbidity rate, with
26% of patients with PsA having autoimmune thyroiditis
[5]. In another study, 20S proteasome autoantibodies were
more frequently detected in PsA patients (27.8%) than in in
healthy controls (0%), as well as more frequently in sys-
temic lupus erythematosus patients (42%) than in rheuma-
toid arthritis patients (5%) [6]. However, the numbers of
patients were small in these studies (36 PsA patients and 30
healthy controls) [6], and, in both studies, no patients with
psoriasis without arthritic manifestations (PsC) were in-
cluded. To date, no specific serological markers discrimin-
ating patients with PsA from patients with PsC have been
identified. Nevertheless, a small but significant occurrence
of B lymphocytes was reported in the skin of patients with
PsA, but not in patients with PsC [7].
Recently, we discovered progranulin autoantibodies
(PGRN Abs) in a protein array-based screening of plasma
from various primary vasculitides and found evidence that
these PGRN Abs have a neutralizing effect on PGRN
plasma levels [8]. PGRN is a secreted precursor protein that
is cleaved at the linker regions between individual granulins
by neutrophil elastase [9], proteinase 3 [10], matrix metal-
loproteinase 12 [11], matrix metalloproteinase 14 [9] and
ADAMTS-7 (a disintegrin and metalloprotease with
thrombospondin motif 7) [12]. Until recently, most re-
search on PGRN had focused on its role in neurodegen-
erative diseases such as frontotemporal lobe dementia
[13]. However, since Tang et al. [14] showed that PGRN
is a high-affinity ligand of the tumour necrosis factor α
(TNF-α) receptors 1 and 2 (TNFR1 and TNFR2) and that
its anti-inflammatory effect is caused by direct inhibition
of these receptors, PGRN has increasingly become the
focus of research on autoimmune diseases.
Recently, Chen et al. [15] challenged the notion of this
interaction of PGRN with TNFR1 and TNFR2 previously
reported by Tang et al. [14], as they could not reproduce
the interaction of PGRN with TNFR1 and TNFR2. How-
ever, they did not question the anti-inflammatory effect
of PGRN [10]. Tang et al. responded in a letter to the
editor that Chen et al. utilized PGRN, which might be
folded improperly. Furthermore, Tang et al. stated that
validation of recombinant PGRN’s functionality based
only on its C-terminal binding to sortilin would be in-
sufficient to determine its quality regarding its other bio-
logical functions, which are not primarily mediated by
PGRN’s C-Terminus. Subsequently, Jian et al. showed in
detail that PGRN binds as TNF-α to cysteine-rich do-
main 2 (CRD2) and CRD3 of TNFR and that proper
folding of PGRN is essential for this binding. Further-
more, dithiothreitol treatment of PGRN, which had beenperformed by Chen et al., abolishes the binding of PGRN
to TNFR but enhances its binding to sortilin [16]. Recently,
two other groups independently reproduced the binding of
PGRN to TNFR1 and TNFR2, and inhibitory effect of this
binding on TNF-α-induced effects [17,18]. Dramatic effects
of PGRN deficiency have been shown in vivo in collagen-
induced arthritis and collagen Ab-induced arthritis mouse
models, resulting in fulminant courses of disease [14]. Fur-
thermore, the administration of recombinant human PGRN
or a recombinant PGRN derivative, antagonist of TNF/
TNFR signalling via targeting to TNF receptors (ATST-
TRIN), that consists of three modified granulin motifs and
their accompanying linker regions [14] had strong anti-in-
flammatory effects comparable to, or even stronger than,
the administration of etanercept [14]. Consequently, PGRN
and ATSTTRIN have been regarded as promising next-
generation TNF-α blockers [19]. In addition to this strong
anti-inflammatory effect mediated by the inhibition of
TNFR1 and TNFR2, several other functions of PGRN in
humans have been reported [20].
Interestingly, the previously detected PGRN Abs showed
neutralizing effects on PGRN plasma levels detected by en-
zyme-linked immunosorbent assay (ELISA) and Western
blot analysis. This observation, given the anti-inflammatory
properties of secreted PGRN, suggested a proinflammatory
effect of PGRN Abs, which was supported by our observa-
tion that the presence of PGRN Abs is associated with ac-
tive disease state in granulomatosis with polyangiitis [8].
Apart from primary systemic vasculitis, we also found neu-
tralizing PGRN Abs in systemic lupus erythematosus as
well as in rheumatoid arthritis [8]. Some of the rheumatoid
arthritis patients with PGRN Abs were actually seronegative
for RF or anticitrullinated protein Abs. Furthermore, PGRN
Abs were detected in patients with spondyloarthritis. This
observation led us to conduct the present study to investi-
gate the presence of PGRN Abs in patients with the sero-
negative disorder PsA, compare it to patients with PsC and
healthy controls and investigate possible functional effects
of PGRN Abs in vitro.
Methods
Study participants
This study was approved by our regional ethical review
committee (Ethikkommission der Ärztekammer des Saar-
landes) and conducted according to the Declaration of
Helsinki. Serum samples of patients with PsA were col-
lected prospectively from patients attending three centres
of rheumatology between October 2011 and July 2012:
Saarland Rheumatology Centre, the Department of Internal
Medicine I at University Hospital in Homburg/ 149 Saar,
the Rheumatology Department of the University Hospital
Frankfurt am Main and the Outpatient Center for Rheuma-
tology in Berlin-Lichtenberg. Sera from patients with PsC
were provided by the Department of Dermatology of
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from healthy controls were also obtained at Saarland Uni-
versity Medical School. All serum specimens were stored at
−80°C at the Department of Internal Medicine I, José Car-
reras Research Centre, Saarland University Medical Centre.
All patients were examined by a rheumatologist (PsA pa-
tients) and a dermatologist (PsC patients) to confirm the
diagnosis of PsA according to the CASPAR criteria or to
exclude PsA in PsC patients. All diagnoses of PsC were
made by dermatologists and confirmed by a rheumatolo-
gist. All PsA patients were stratified into subgroups accord-
ing to gender, age, presence or absence of manifestations of
axial disease, enthesitis, dactylitis and therapeutic regimens
such as TNF-α blocker–containing medication. Axial dis-
ease was defined by positive findings on X-rays or magnetic
resonance imaging scans for spondyloarthritis and/or
sacroiliitis. Patients were considered positive for enthesitis
or dactylitis on the basis of a positive diagnosis during the
course of disease; however, no imaging findings have been
required. No subgroup stratification for patients with PsC
was performed, because the PGRN Ab serostatus of all pa-
tients with PsC was negative. All patients and healthy con-
trols gave their written informed consent to participate in
the study.
Progranulin antibody enzyme-linked immunosorbent
assay
The ELISA for PGRN Abs was performed as previously
described [8]. In short, the GRN gene encoding PGRN was
recombinantly expressed with a C-terminal FLAG-tag in
HEK293 cells under the control of a cytomegalovirus
promoter (pSFI). Total cell extracts were prepared and
bound to Nunc MaxiSorp plates (eBioscience, Frankfurt,
Germany) precoated with murine anti-FLAG mAb at a di-
lution of 1:2,500 (v/v; Sigma-Aldrich, Munich, Germany) at
4°C overnight. Blocking was performed with 1.5% (w/v) gel-
atin in Tris-buffered saline (TBS), and washing steps were
performed with TBS with Triton X-100. The individual
serum samples were diluted 1:100. ELISA was performed
according to standard protocols with the following Abs: bi-
otinylated goat antihuman heavy and light chain immuno-
globulin G (IgG) at a dilution of 1:2,500 (Dianova,
Hamburg, Germany); subclass-specific sheep antihuman
IgG1, IgG2, IgG3 and IgG4 (Binding Site Group, Birming-
ham, UK) at dilutions of 1:5,000; goat antihuman IgM (Dia-
nova) at a dilution of 1:2,500; or goat antihuman IgA
(Dianova) at a dilution of 1:2,500. Following this step, corre-
sponding biotinylated secondary Abs were used for immu-
noassays carried out to detect IgG subclasses and IgM.
Peroxidase-labelled streptavidin (Roche Applied Science,
Indianapolis, IN, USA) was used at a dilution of 1:50,000.
As a cutoff for positivity, the average of the optical density
(OD) of the negative samples plus three standard deviations
was applied.Progranulin plasma levels measured by enzyme-linked
immunosorbent assay
PGRN plasma levels were determined with a commer-
cially available ELISA kit (AdipoGen, Incheon, South
Korea) according to the manufacturer’s instructions. The
median of the plasma PGRN level of the healthy control
group was set at 100% [8].
Cytotoxicity assay
A nonradioactive cytotoxicity assay (EZ4U Cell Proliferation
Assay; Biomedica, Vienna, Austria) was performed ac-
cording to the manufacturer’s instructions. For this
TNF-α-induced cytotoxicity assay, we used the highly
TNF-α-sensitive mouse fibrosarcoma WEHI-S cell line
as the target cells [21]. The interaction of human re-
combinant PGRN with murine TNFR1 and TNFR2 was
previously demonstrated in vitro and in vivo [14], and,
moreover, human PGRN Abs bind murine PGRN
(Additional file 1). As a human control target cell line, the
TNF-α-sensitive HT-1080 fibrosarcoma cell line was used.
In short, 4 × 104 WEHI-S cells or 4 × 104 HT-1080
cells were seeded into 200 μl of cell culture at 37°C and
5% CO2. To detect possible differences between added
sera of patients with PsA with and without PGRN Abs,
of patients with PsC, and of healthy controls, serum of a
PGRN Ab-positive patient with PsA, serum of a matched
PGRN Ab-negative patient with PsA, serum of a patient
with PsC and serum of a healthy control were added in
dilutions from 1:4 to 1:512 to cultured WEHI-S cells and
HT-1080 cells, followed by administration of TNF-α
(100 pg/ml). Serum samples from gender-, age-, disease-
and therapy modality-matched patients were chosen.
Serum samples from patients receiving TNF-α blockers
or other biologicals were excluded. WEHI-S cells and
HT-1080 cells without addition of TNF-α and serum, or
solely with addition of TNF-α (100 pg/ml), were used as
positive and negative controls. After 24-hour incubation
at 37°C, 20 μl of chromophore substrate were added to
each well. This chromophore substrate is converted only
by vital cells. The adsorption of the product was mea-
sured at an OD of 450 nm.
Statistical analyses
Differences in age and gender between the populations
of PsA patients, PsC patients and healthy controls were
tested by Student’s t-test. Different frequencies of PGRN
Abs in the serum samples of patients with PsA and PsC
were analysed by χ2 test. Differences in the frequency of
PGRN Abs between PsA patients after stratification into
subgroups were also tested with the χ2 test. For analysis
of the differences in PGRN plasma levels between healthy
controls, PGRN Ab-positive and PGRN Ab-negative pa-
tients with PsA and seronegative patients with PsC, the
Mann–Whitney U test was applied. A two-sided test value
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statistical analyses were performed in SPSS version 19.0
for Windows software (IBM SPSS, Chicago, IL, USA).
Results
Patient characteristics
The patients’ characteristics are outlined in Table 1.
Frequency, titres and immunoglobulin G subclass of
progranulin antibodies
Of 260 patients with PsA, 50 (19.23%) had PGRN Abs in
their sera. No PGRN Abs were found in the sera of 100
patients with PsC (0%; P = 0.0001). Of 97 healthy
controls, 1 (1.03%) had PGRN Abs (Figure 1a). PGRN
Ab-positive patients had titres ranging from 1:400 to
1:1,600 (Figure 1b). The sera of the 50 PGRN Ab-
positive PsA patients were tested for their Ig class.
PGRN Abs belonged exclusively to IgG (50 of 50 pa-
tients). PGRN Abs were not detected for either IgA or
IgM (Additional file 1). Subsequently, IgG subclasses of
PGRN Abs were determined. The PGRN Abs in 44 pa-
tients (88%) belonged to the IgG1 subclass, 1 (2%) of 50
belonged to the IgG2 subclass, 5 (10%) 50 belonged to the
IgG3 subclass and 0 (0.0%) of 50 belonged to the IgG4
subclass (Figure 1c).
Analysis of the progranulin-positive patients with psori-
atic arthritis
All 260 PsA patients (210 PGRN Ab-negative, 50 PGRN
Ab-positive) were stratified according to their clinical
manifestations, such as enthesitis, dactylitis, axial mani-
festations and erosive-proliferative joint damage. Patients
with PsA were also analysed in subgroups according to
age at primary diagnosis, gender, human leucocyte antigen
B27 status and treatment with TNF-α-blocking agentsTable 1 Characteristics of patients with psoriatic arthritis
and psoriasis without arthritis
Characteristics PsA PsC
Median age (min–max) 54 (24–81) 53 (16–80)
Gender, M/F (%) 43.5/56.4 64/36
Age at psoriasis diagnosis, years 35 33
Age at PsA diagnosis, years 46
Enthesitis (%)a 39.5
Dactylitis (%) 39.2
Axial disease (%) 27.7
Erosive (%)b 44.9
HLA-B27-positive (%) 32.7
DMARD (%)c 48.8
TNF-α blockers (%)d 18.4
DMARD: disease-modifying antirheumatic drug; HLA-B27: human leucocyte
antigen B27; PsA: psoriatic arthritis; PsC: psoriasis without arthritic manifestations;
TNF-α: tumour necrosis factor α. Missing data: an = 69, bn = 24, cn = 29, dn = 9.(Figure 2). Although there was no difference between
PGRN Ab-positive and PGRN Ab-negative patients with
respect to age at the time of PsA diagnosis, PGRN Ab-
positive patients were significantly older (>50 years) than
PGRN Ab-negative patients with PsA (21% vs. 15.4%; P =
0.016). PsA patients with either enthesitis or dactylitis had
significantly higher frequencies of PGRN Abs (P = 0.001
and P = 0.026, respectively, compared to patients with PsA
without enthesitis or dactylitis), whereas no statistically
significant associations were found for axial manifes-
tations or erosive joint destruction and PGRN Ab positiv-
ity. In addition, significantly more patients receiving
TNF-α blocker treatment had PGRN Abs compared to
patients receiving therapy without TNF-α blockers (20.8%
vs. 17.4%; P = 0.016).
Progranulin plasma levels
PGRN plasma levels were significantly lower in PGRN
Ab-positive patients with PsA (n = 10) compared to
healthy controls (n = 10) (P < 0.001 by Mann-Whitney
U test), patients with PsC (n = 10) (P < 0.001 by Mann-
Whitney U test) and PGRN Ab-negative patients with
PsA (n = 5) (P < 0.001 by Mann-Whitney U test). Further-
more, PGRN Ab-negative patients with PsA had signifi-
cantly lower plasma levels of PGRN than healthy controls
(P = 0.019 by Mann-Whitney U test). There was also a
tendency toward lower PGRN plasma levels in PGRN
Ab-negative patients with PsA than in patients with PsC
(P = 0.055 by Mann-Whitney U test) (Figure 3).
Cytotoxicity assay
In the TNF-α-induced cytotoxicity assays, we analysed
the protective effects of sera from healthy controls, pa-
tients with PsC and PGRN Ab-positive or PGRN Ab-
negative patients with PsA. The addition of sera from
healthy controls, patients with PsC and PGRN Ab-negative
patients with PsA reduced TNF-α-induced cytotoxicity of
WEHI-S and HT-1080 cells to a significantly higher degree
than in the sera of PGRN Ab-positive patients with PsA.
This difference was significant up to a serum dilution of
1:64 (Figures 4a and 4b).
Discussion
In the present study, we report the presence of PGRN
Abs in relevant titres in a subgroup of patients with PsA
(Figures 1a and b). These PGRN Abs had previously
been found frequently in primary vasculitis, systemic
lupus erythematosus and rheumatoid arthritis, but not at
all or very infrequently in controls. Despite the obvious
lack of specificity for PsA, PGRN Abs are of particular
interest because they had a neutralizing effect on PGRN
plasma levels detected by ELISA and Western blot
analysis [8]. PGRN is known to be a strong secreted
anti-inflammatory mediator [10] by direct inhibition
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hypothesis of a proinflammatory effect of PGRN Abs,
as demonstrated by the loss of protective effects of
PGRN in the presence of PGRN Abs containing PsA
sera in TNF-α-mediated cytotoxicity assays (Figures 4a
and 4b). Our results support the observation by Tang
et al. of a direct inhibitory effect of PGRN on TNFR1
and TNFR2 and that administration of recombinanthuman PGRN protects cells from cytotoxic effects of
TNF-α in vitro [14,16]. Given the fact that the half-
life of PGRN is about 40 hours [14], in contrast to
the short half-life of TNF-α (typical for cytokines) of
20 minutes [22], the effects of the intrinsic TNF-α in
the serum of patients and controls is negligible. Our
cytotoxicity assays revealed clear differences between
the effects of serum from PGRN Ab-positive patients
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Figure 2 Progranulin antibodies in subpopulations of patients with psoriatic arthritis. The columns represent the percentage of
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PGRN Ab-negative patients with PsA, patients with
PsC or healthy controls on the other hand. The ad-
ministration of serum samples of patients with PsA
with neutralizing PGRN Abs, and thus with lower
PGRN levels, protected the WEHI-S and HT-1080
cells from the cytotoxic effects of TNF-α far less than
serum samples from patients with PsA without PGRN
Abs, patients with PsC or healthy controls. This find-
ing clearly proves the proinflammatory effect of neu-
tralizing PGRN Abs in vitro.Figure 3 Association of progranulin antibody status and progranulin
were determined in patients with psoriasis without arthritic manifestations
psoriatic arthritis (PsA) (n = 10), PGRN Ab-negative patients with PsA (n = 5
50% (median) and 75% (box) percentiles and the range (line). Median PGRNThe second important finding of the present study is
that PGRN Abs were observed in patients with PsA, but
not in patients with PsC (Figure 1). Interestingly, Veale
et al. reported small but significant numbers of B cells
in the skin of patients with PsA, but not in the skin of
patients with PsC or in healthy controls [7]. In the
present study, the occurrence of PGRN Abs in patients
with PsA was associated with different clinical character-
istics. PsA patients with dactylitis and enthesitis had
PGRN Ab more frequently than PsA patients without
such manifestations. Moreover, patients with PsA whoplasma levels in psoriasis patients. Progranulin (PGRN) plasma levels
(PsC) (n = 10), PGRN antibody (PGRN Ab)-positive patients with
) and in healthy controls (n = 10). Data are presented as 25% (box),
plasma level obtained from healthy controls was set at 100%.
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had PGRN Abs slightly more frequently (20.8% versus
17.4%), indirectly suggesting that PGRN Abs might be
associated with a more aggressive course of disease, ne-
cessitating more intensive treatment. Generally, the
grades of dactylitis and enthesitis in PsA patients have
been suggested to be partly influenced, that is, enhanced,
by TNF-α, which is supported by the efficacy of TNF-α
blockers in PsA therapy [23-26]. Given the neutralizing
effect of PGRN Abs on PGRN plasma levels in PsA pa-
tients (Figure 3), as well as in other autoimmune dis-
eases [8], and, more important, given the results of the
functional in vitro assays indicating a sensitizing effect
of PGRN Abs for the effects of TNF-α in patients with
PsA, a higher prevalence of PGRN Abs in patients with
TNF-α-induced disease manifestations such as enthesitis
and dactylitis could obviously be expected. Despite the
statistical significance of our results, however, therelative differences in the frequency of PGRN Abs
between the various subgroups were rather small (PGRN
Ab-positive enthesitis 21.3% vs. PGRN Ab-negative
enthesitis 14.7% and PGRN Ab-positive dactilytis 21.8%
vs. PGRN Ab-negative enthesitis 15.4%). These results
could be explained by the relatively small absolute num-
bers of patients with subentities and partly by missing
data concerning dactylitis and enthesitis. Moreover, we
observed a statistically nonsignificant trend between the
occurrence of PGRN Abs and the presence of erosive
joint disease (P = 0.061). In consideration of the sus-
pected pathogenic proinflammatory effect of PGRN Abs
disrupting the physiologic homeostasis of TNF-α/PGRN
agonists and antagonists in a subgroup of patients with
PsA, PGRN Abs might be of use as prognostic markers
for the course of disease and/or as predictive markers
for the effectiveness of TNF-α-blocking agents. Theoret-
ically, the identification of neutralizing PGRN Abs in
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apy because patients with PGRN Abs have lower physio-
logic TNF-α antagonist levels and might profit from
dose intensification of TNF-α blockers. From this point
of view, prospective studies of patients with PsA are
needed to evaluate PGRN Abs as possible biomarkers
for the diagnosis, risk stratification and choice of ad-
equate treatment modality.
Conclusion
Neutralizing PGRN Abs occurred in relevant titres in a
subgroup of patients with PsA, but not in PsC patients.
PGRN Ab-positive patients with PsA had more fre-
quently enthesitis and dactylitis than PGRN Ab-negative
patients with PsA. Moreover in TNF-α-induced cytotox-
icity assays using WEHI-S and HT-1080 cells, the pro-
tective effects of PGRN were inhibited by PGRN Ab-
containing sera of patients with PsA. This suggests that
PGRN Abs not only may be useful as a diagnostic and
prognostic marker but also may be involved in the patho-
genesis of the arthritic process in a subgroup of patients
with PsA.Additional file
Additional file 1: Figure S1. Immunoglobulin class of progranulin
(PRGN) antibodies (Abs) in psoriatic arthritis. Each PGRN Ab-containing
serum was tested for immunoglobulin (Ig) class of PGRN Abs. (a) PGRN
Abs were tested for IgG class. (b) PGRN Abs were tested for IgA class.
(c) PGRN Abs were tested for IgM class. (d) PGRN Abs were tested for
IgG1 subclass. (e) PGRN Abs were tested for IgG2 subclass. (f) PGRN Abs
were tested for IgG3 subclass. (g) PGRN Abs were tested for IgG4
subclass. Sera were used at a dilution of 1:100.Abbreviations
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